Clinical Trial: Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial
Brief Summary: -IgA nephropathy is the most common primary glomerular disease in China, Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease. The purpose of this study is to evaluate the safety and efficacy of Abelmoschus manihot for treating IgA nephropathy in large scale samples with long time take.
Detailed Summary: The test has not been completed .
Sponsor: Chen Xiangmei
Current Primary Outcome: Change in 24-h proteinuria from baseline after treatment [ Time Frame: Baseline(week 0), week 4, week 12, week 24, week 36, week 48 ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Change in serum creatinine from baseline after treatment [ Time Frame: Baseline(week 0), week 4, week 12, week 24, week 36, week 48 ]
- Change in estimated glomerular filtration rate (eGFR) from baseline after treatment [ Time Frame: Baseline(week 0), week 4, week 12, week 24, week 36, week 48 ]
Original Secondary Outcome: Same as current
Information By: Chinese PLA General Hospital
Dates:
Date Received: August 30, 2014
Date Started: September 2014
Date Completion: December 2017
Last Updated: July 4, 2016
Last Verified: July 2016
